Free press releases distribution network?

More news: Health/Surgery
Agency / Source: PMR Corporate

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Clinical Market in CIS to Exceed €700m in 2014 Finds PMR Corporate - Clinical trials in the CIS countries have been developing in a positive fashion (with the exception of Russia, whose development slowed for a while as a result of significant changes in regulation) - PMRCorporate.com
Clinical Market in CIS to Exceed €700m in 2014 Finds PMR Corporate

 

PRZOOM - /newswire/ - Cracow, Malopolskie, Poland, 2012/02/10 - Clinical trials in the CIS countries have been developing in a positive fashion (with the exception of Russia, whose development slowed for a while as a result of significant changes in regulation) - PMRCorporate.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The average increase in value is expected to reach 14% and the average increase in volume approximately 13% between 2012 and 2014, according to the latest PMR report “Clinical trials in CIS countries 2012 – Russia, Ukraine, Belarus and Georgia. Development forecasts for 2012-2014”. Despite some turmoil in legislation, these countries will attract investors because of their relatively low costs and the substantial numbers of people willing to participate in clinical trials.

Russia accounts for over 60% of market value
According to our estimates, the overall clinical trial market value of the CIS countries analysed exceeded $532m (€403m) in 2010 and reached $633 (€479m) in 2011 (a 19% year-on-year increase). The largest proportion of this value was accounted for by Russia – 63%, whereas the figure for Ukraine was 33% in 2011.

Political and legal situation crucial for development of clinical trials
“The rate of change of development over the next few years depends on many factors, and those of a political nature in particular. If there are no unexpected events, the market is expected to be worth more than $940m (€712m) in 2014.” Monika Stefanczyk. Head Pharmaceutical Market Analyst estimated. Market players canvassed by PMR observed that the situation pertaining to clinical trials in Russia could change after the parliamentary election due on March 2012. We expect an increase in the market growth rate if appropriate changes in current legislation (making the clinical trial approval process less complicated and time-consuming) are implemented. For the time being, the market in Russia could also accelerate because of new regulations which require conducting more clinical trials and Pharma 2020 plan.
The political situation in Belarus is not expected to change in the near future, and the country’s political isolation from the EU and US will, therefore, continue to hinder the development of clinical trials in this country.

In Ukraine, which has been recently relatively stable politically, it is important to retain this stability in order to continue to develop clinical trials.
It is worthy of note that all of the countries analysed need to compete with other emerging countries. As they are not EU members and are not in the Schengen zone, only a small percentage of their considerable potential has been used. For example, Ukraine uses only 10-15% of its potential, according to European Business Association data. The relatively modest value of these markets and their vast potential are the reasons of the predicted rate of development of Ukraine and Georgia of at least 10-20% over the next three years.

Increase of approximately 13% per annum in number of clinical trials between 2011 and 2014
There was a reduction in the number of newly registered clinical trials in selected CIS countries in 2009 and 2010, when the economic crisis severely affected the market. In 2009 the number of new clinical trials fell by almost 100. The situation reached its nadir, in terms of the number of new clinical trials registered, in 2010, when new legislation on clinical trials came into force in Russia. As Russia is the largest local market, this affected the joint results of all four countries, although Ukraine, for example, experienced growth in 2010. In 2011 alone the CIS market is expected to achieve growth of almost 13%. Between 2012 and 2014 the rate of growth of the number of new clinical trials is expected to be between 12 and 13%, reaching 1,177 trials in 2014.

Russia is the undoubted leader among the CIS countries in terms of both the number of on-going (708) clinical trials and the total (1,796). Estimates suggest that the number of clinical trials conducted every year is 600. Ukraine, with 320 on-going clinical trials, is the second largest market in the CIS. However, in the European arena both countries are relatively marginal. In Germany, which is the European leader, the total number of clinical trials is 8,292. Poland, with a 38,200, 000-strong population, is actively engaged in 2,512 trials. A comparison with the Russian and Ukrainian populations (141,900, 000 and 45,900, 000) reveals little market saturation and vast untapped potential in these countries.

This press release is based on information contained in the latest PMR report entitled “Clinical trials in CIS countries 2012 – Russia, Ukraine, Belarus and Georgia. Development forecasts for 2012-2014”.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: PMR Corporate

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Clinical Market in CIS to Exceed €700m in 2014 Finds PMR Corporate

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: PMRCorporate.com 
+48-12 618 90 00 marketing[.]pmrcorporate.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PMR Corporate securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From PMR Corporate / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Ultimate Medical Group Announces A New Regenerative Medicine Division

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today